Clinical Trials Logo

Relapsing Multiple Sclerosis clinical trials

View clinical trials related to Relapsing Multiple Sclerosis.

Filter by:

NCT ID: NCT05199571 Active, not recruiting - Clinical trials for Relapsing Multiple Sclerosis

Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

Start date: July 22, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ofatumumab s.c. in adult participants with relapsing multiple sclerosis (RMS) in China.

NCT ID: NCT05156281 Recruiting - Clinical trials for Relapsing Multiple Sclerosis

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

REMODEL-2
Start date: December 13, 2021
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

NCT ID: NCT05147220 Recruiting - Clinical trials for Relapsing Multiple Sclerosis

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis

Start date: December 16, 2021
Phase: Phase 3
Study type: Interventional

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis

NCT ID: NCT05119569 Active, not recruiting - Clinical trials for Relapsing Multiple Sclerosis

A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)

FENopta
Start date: March 1, 2022
Phase: Phase 2
Study type: Interventional

This is a study evaluating the effect of fenebrutinib on brain magnetic resonance imaging (MRI) in participants with RMS. The safety and pharmacokinetics of fenebrutinib will also be evaluated. Participants will be randomized to receive either fenebrutinib or placebo.

NCT ID: NCT05090033 Recruiting - Clinical trials for Relapsing Multiple Sclerosis

Characterizing the Use of Ofatumumab in a Real World Setting

EAFToS
Start date: December 8, 2022
Phase:
Study type: Observational

This is a non-interventional primary use of data study utilizing de-identified patient-level onboarding and adherence data managed through the MSGo patient support service platform and includes a sub-study to explore the impact of ofatumumab on relevant patient reported outcomes (PROs) with respect to clinical outcomes.

NCT ID: NCT05077956 Withdrawn - Multiple Sclerosis Clinical Trials

Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis

Sema4A MS
Start date: October 19, 2021
Phase:
Study type: Observational

Measure serum and cerebrospinal fluid Sema4A levels in female subjects with newly diagnosed and untreated relapsing multiple sclerosis, clinically stable relapsing multiple sclerosis receiving disease modifying therapy, relapsing multiple sclerosis receiving disease modifying therapy with breakthrough disease, or non-multiple sclerosis controls (patients without inflammatory central nervous system disease).

NCT ID: NCT04964791 Recruiting - Clinical trials for Relapsing Multiple Sclerosis

RMS Study of BTK Inhibitor SAR442168

Start date: August 1, 2020
Phase:
Study type: Observational

To access SAR442168 in the RMS populstion. Efficaty will be accessed by adjudicated relapse rate, disability progression, and MRI findings of disease activity.

NCT ID: NCT04928313 Completed - Clinical trials for Relapsing Multiple Sclerosis

Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran

Start date: April 12, 2015
Phase:
Study type: Observational

This trial was an obsevational phase IV prospective multicenter study designed to evaluate the safety and effectiveness of Cinnomer® in patients with MS in Iran. The primary objective of this study was safety assessment of Cinnomer® Secondary objectives were: - Effectiveness assessment of Cinnomer® - Assessment of the patients' QoL - Evaluation of the patients' depression status

NCT ID: NCT04847596 Completed - Clinical trials for Relapsing Multiple Sclerosis

A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Start date: May 21, 2021
Phase:
Study type: Observational

This is a single arm, pilot multicenter prospective study in up to 22 participants with relapsing multiple sclerosis. Patients screened for the study can either be scheduled for vaccine, have received a single vaccine with a scheduled second dose, or already completed full course (two dose) vaccination. Fully vaccinated participants must be able to complete immune assay No.1 ≥ 14 days after the second dose of vaccine

NCT ID: NCT04667117 Completed - Clinical trials for Relapsing Multiple Sclerosis

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Start date: January 14, 2021
Phase: Phase 4
Study type: Interventional

To assess whether participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once every 4 weeks (q4) can mount an adequate immune response to inactivated influenza vaccine as measured by humoral responses compared to participants on an iDMT.